Long-Term Control after Intermittent Reintroduction of Enfortumab Vedotin in Metastatic Urothelial Carcinoma: A Case Report
Temporary discontinuation of EV due to AEs followed by intermittent reintroduction resulted in long-term disease control in this patient with mUC. This case suggests that rechallenging EV after treatment interruption may be a feasible approach in selected patients, underscoring the importance of careful AE management in real-world practice.
Authors
- Takayuki Takahashi (ORCID: https://orcid.org/0009-0009-5721-3705)
- Yuta Umezawa
- Go Kaneko (ORCID: https://orcid.org/0000-0002-1796-7301)
- Suguru Shirotake (ORCID: https://orcid.org/0000-0002-3581-2039)
- Kimiharu Takamatsu (ORCID: https://orcid.org/0000-0002-3325-6606)
- Masayuki Hagiwara (ORCID: https://orcid.org/0000-0002-8680-2324)
- Masafumi Oyama (ORCID: https://orcid.org/0000-0002-4887-5522)
- Daisuke Igarashi
- Shohei Yamamura (ORCID: https://orcid.org/0000-0002-4971-4560)
- Kenta Fujii
Institutions
- Saitama Medical University (JP)
Publication Details
- Journal
- Case Reports in Oncology
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1159/000549571
- Citations
- 1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.01